NCT07016438

Clinical Study of PAL-222 Targeting Patients With Refractory Skin Ulcer

Phase I/IIa Clinical Study of PAL-222 Targeting Patients With Refractory Skin Ulcer

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 6 (estimated)
• Sponsor: PharmaBio Corporation · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to assess safety and efficacy in patients with with Refractory skin ulcer no response to existing therapy. The main measures it aims to answer are: * Investigation of adverse events * Changes in clinical testing data * Changes in vital signs Participants will have one PAL-222 transplanted to the ulcer site. Researchers will compare before and after the transplantation to see if any safety issues are recognized.

Conditions

• Refractory Skin Ulcer

Interventions

Type	Name	Description
PROCEDURE	Transplant surgery	One piece of PAL-222 is implanted into the ulcer area through the surgical procedure.

Timeline

• Start date: 2025-04-15
• Primary completion: 2025-12-01
• Completion: 2025-12-31
• First posted: 2025-06-11
• Last updated: 2025-06-11

Locations

1 site across 1 country: Japan